Literature DB >> 23129228

Stabilization of the prostate-specific tumor suppressor NKX3.1 by the oncogenic protein kinase Pim-1 in prostate cancer cells.

Achuth Padmanabhan1, Eliza B Gosc, Charles J Bieberich.   

Abstract

Loss of NKX3.1 is an early and consistent event in prostate cancer and is associated with increased proliferation of prostate epithelial cells and poor prognosis. NKX3.1 stability is regulated post-translationally through phosphorylation at multiple sites by several protein kinases. Here, we report the paradoxical stabilization of the prostate-specific tumor suppressor NKX3.1 by the oncogenic protein kinase Pim-1 in prostate cancer cells. Pharmacologic Pim-1 inhibition using the small molecule inhibitor CX-6258 decreased steady state levels and half-life of NKX3.1 protein but mRNA was not affected. This effect was reversed by inhibition of the 26S-proteasome, demonstrating that Pim-1 protects NKX3.1 from proteasome-mediated degradation. Mass spectrometric analyses revealed Thr89, Ser185, Ser186, Ser195, and Ser196 as Pim-1 phospho-acceptor sites on NKX3.1. Through mutational analysis, we determined that NKX3.1 phosphorylation at Ser185, Ser186, and within the N-terminal PEST domain is essential for Pim-1-mediated stabilization. Further, we also identified Lys182 as a critical residue for NKX3.1 stabilization by Pim-1. Pim-1-mediated NKX3.1 stabilization may be important in maintaining normal cellular homeostasis in normal prostate epithelial cells, and may maintain basal NKX3.1 protein levels in prostate cancer cells.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23129228     DOI: 10.1002/jcb.24444

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

Review 1.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

2.  Protein kinase A regulates MYC protein through transcriptional and post-translational mechanisms in a catalytic subunit isoform-specific manner.

Authors:  Achuth Padmanabhan; Xiang Li; Charles J Bieberich
Journal:  J Biol Chem       Date:  2013-03-15       Impact factor: 5.157

3.  Zinc Oxide nanoparticles induce oxidative and proteotoxic stress in ovarian cancer cells and trigger apoptosis Independent of p53-mutation status.

Authors:  Achuth Padmanabhan; M Kaushik; R Niranjan; JoAnne S Richards; Brandon Ebright; G Devanand Venkatasubbu
Journal:  Appl Surf Sci       Date:  2019-09       Impact factor: 6.707

4.  USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells.

Authors:  Achuth Padmanabhan; Nicholes Candelaria; Kwong-Kwok Wong; Bryan C Nikolai; David M Lonard; Bert W O'Malley; JoAnne S Richards
Journal:  Nat Commun       Date:  2018-03-28       Impact factor: 14.919

5.  PIM1 promotes hepatic conversion by suppressing reprogramming-induced ferroptosis and cell cycle arrest.

Authors:  Yangyang Yuan; Chenwei Wang; Xuran Zhuang; Shaofeng Lin; Miaomiao Luo; Wankun Deng; Jiaqi Zhou; Lihui Liu; Lina Mao; Wenbo Peng; Jian Chen; Qiangsong Wang; Yilai Shu; Yu Xue; Pengyu Huang
Journal:  Nat Commun       Date:  2022-09-06       Impact factor: 17.694

6.  LIMK2-NKX3.1 Engagement Promotes Castration-Resistant Prostate Cancer.

Authors:  Moloud A Sooreshjani; Kumar Nikhil; Mohini Kamra; Dung N Nguyen; Dinesh Kumar; Kavita Shah
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

7.  MicroRNA-124-3p regulates cell proliferation, invasion, apoptosis, and bioenergetics by targeting PIM1 in astrocytoma.

Authors:  Danni Deng; Lei Wang; Yao Chen; Bowen Li; Lian Xue; Naiyuan Shao; Qiang Wang; Xiwei Xia; Yilin Yang; Feng Zhi
Journal:  Cancer Sci       Date:  2016-06-21       Impact factor: 6.518

Review 8.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.